Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "PATsmart REBEL XT At-line Media Analyzer"

Looking for quality documents?
external link icon
Repligen Appoints Nicolas M. Barthelemy to Board of Directors
WALTHAM, Mass., June 12, 2014 (GLOBE NEWSWIRE) - Repligen Corporation today announced that it has elected life sciences and biopharmaceutical industry veteran Nicolas M. Barthelemy to its Board of Directors. Mr. Barthelemy brings over 20 years of industry experience to the director role, most recently as President, Global Commercial Operations at Life Technologies, a multinational life sciences company whose acquisition by Thermo Fisher Scientific was completed earlier this year. Mr. Barthelemy is particularly accomplished in the areas of commercial expansion and global market development, supported by his strong background in biologic drug manufacturing and supply chain management. "I am pleased to welcome Nicolas Barthelemy as a fitting addition to the Repligen Board," said Walter C. Herlihy, President and Chief Executive Officer of Repligen. "Mr. Barthelemy's input will have immediate value as we expand our commercial organization to market our growing portfolio of proprietary
external link icon
Repligen Appoints Jonathan I. Lieber as CFO
- Former CFO of Xcellerex, Inc. Joins Repligen Executive Management Team - Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jonathan I. Lieber to the position of Chief Financial Officer and Treasurer, effective immediately. Mr. Lieber most recently held the position of CFO and Treasurer at Xcellerex, Inc., a supplier of bioprocessing products and disposable biomanufacturing technologies, which was acquired in May 2012 by GE Healthcare. He will be responsible for leading Repligen’s financial activities, including long-term financial strategy and risk management. Repligen’s current CFO William J. Kelly has been named Chief Accounting Officer, overseeing the Company’s accounting and management reporting functions, as well as its internal controls. “We are pleased to welcome Jonathan Lieber to the CFO role,” said Walter C. Herlihy, Ph.D., President and Chief Executive Officer at Repligen. “Over the past nine months, Repligen has become a profitable, significantly
external link icon
Repligen Announces Market Launch of OPUS® 80R, Reinforces Technology Leadership in Pre-Packed Chromatography
- First and only available 80 cm diameter pre-packed column to address large-scale clinical and commercial-scale manufacturing of biological drugs -
WALTHAM, Mass., March 20, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its next-generation OPUS® column, the OPUS 80R, which is the largest pre-packed column on the market and is suitable for late-stage clinical into commercial-scale manufacturing of biological drugs. OPUS columns are used in downstream manufacturing processes, to purify biologics including monoclonal antibodies, recombinant proteins, vaccines and gene therapies. The OPUS product line is the industry’s broadest and most scalable with packed bed volumes now ranging from 50 microliters to 150 liters. The groundbreaking OPUS 80R columns are being highlighted in a Technology Workshop on March 21 st at the BioProcess International West
external link icon
Repligen Completes Expansion of U.S. Manufacturing Facility
WALTHAM, Mass., Nov. 1, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced it has completed a 9,000 square foot expansion of its manufacturing facilities at its Waltham headquarters to meet growth in demand for its bioprocessing products and to ensure that the quality, capacity and support needs of its customers continue to be met. A dedicated production suite more than doubles capacity for the Company's OPUS ® line of pre-packed chromatography columns, with cleanrooms built to ISO 7 specifications providing an appropriately controlled environment to satisfy the Good Manufacturing Practices (GMP) standards of the Company's biopharmaceutical customers. "This expansion will enable us to meet the critical needs of our customers for quality and timely delivery," said Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen. "The new cleanroom suite enables us to produce OPUS ® columns under the highest quality standard demanded by
publications icon
Evaluating DNA purity ratio determination with the CTech™ SoloVPE® System White Paper
Spectrophotometric analysis is one of the most common techniques used to quantitate nucleic acids in a solution. However, traditional fixed-pathlength spectrophotometers have limitations when determining the purity ratios of these molecules. In this study, the CTechTM SoloVPE system assessed theoretical DNA purity ratios by utilizing its variable pathlength method, known as Slope Spectroscopy. The method was evaluated by assessing the specificity, intermediate precision, repeatability, linearity, and accuracy of the theoretical purity ratios. The observed purity ratios from the SoloVPE system demonstrated great comparison to the theoretical purity ratios, verifying the SoloVPE system’s slope spectroscopy method to be preferable for this application. Authors: Nigel Herbert, Drusha Purohit, Hannah Mignault
news icon
Repligen Launches the CTech™ SoloVPE® PLUS System
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE® PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers. The SoloVPE PLUS System is engineered to offer unparalleled accuracy, speed, and ease-of-use for at-line ultraviolet-visible (UV-Vis) concentration measurement in complex biological production workflows, from process development scale through cGMP manufacturing.
external link icon
Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification
Complements Stainless Steel ATF Technology with Innovative Single-Use Format Improves Ease of Use for Biopharmaceutical Manufacturing Customers Offers Equivalent High Performance to Stainless Steel XCell™ ATF With Faster Implementation WALTHAM, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its single-use version of XCell™ ATF, a proprietary cell retention system used by biologic drug manufacturers to intensify cell culture and improve the efficiency and productivity of upstream processes. This innovative new single-use format, which will be offered alongside the existing stainless steel line, significantly reduces implementation time and improves overall ease of use for Repligen’s biopharmaceutical manufacturing customers. The new XCell ATF format aligns with single-use and continuous processing workflows that biomanufacturers are increasingly
external link icon
Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova
Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applications Expands Repligen’s Fluid Management portfolio, complements single-use bag offering WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Metenova AB (Metenova) of Mölndal, Sweden. Metenova is projected to generate revenues of $24 million to $25 million for fiscal year 2023, led by the success of its magnetic mixing and drive train technologies that are widely used by global biopharmaceutical companies and contract development and manufacturing organizations (CDMOs). The company recently entered the single-use mixing market with the launch of its MixOne platform, leveraging the success of its existing stainless steel (repeat-use) product line.
external link icon
Repligen Corporation and Spectrum, Inc. to Join Forces
- Adds to Repligen a leader in bioprocess filtration with expertise in hollow fiber technology
- Strengthens flagship XCell™ ATF product line with an extensive filtration consumables portfolio
- Diversifies markets beyond monoclonal antibody manufacturing into vaccine, recombinant protein and gene therapy production
- Expands global commercial organization and adds direct sales in the US, Europe and Asia
- Deal expected to be accretive to Repligen earnings per share in fiscal 2018 WALTHAM, Mass., June 23, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive merger agreement with privately-held Spectrum, Inc. (“Spectrum”) for approximately $359 million, comprised of $120 million in cash plus 6,154,000 shares of Repligen stock. Spectrum recorded revenue of $40.2 million in 2016, with greater than 90% coming from its filtration
external link icon
Repligen Announces Agreement to Acquire Engineered Molding Technology
Expands Single-Use Portfolio with Expertise in Silicone Molding and Tubing WALTHAM, Mass., June 29, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Albany, New York based Engineered Molding Technology (“EMT”), an innovator and manufacturer of single-use silicone assemblies and components used in the manufacturing of biologic drugs. EMT’s standard and custom molded and over-molded connectors and silicone tubing products are key components in single-use filtration and chromatography systems.
Tony J. Hunt, President and CEO of Repligen, said, “The acquisition of EMT expands our line of single-use ProConnex® flow paths, streamlines our supply chain for ATF, and gives us more flexibility as we scale and expand our single-use and systems portfolios.” He continued, “The EMT portfolio also enables us to offer bioprocessing customers
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support